Table 1. Clinical characteristics for the discovery and validation group.
| All | Discovery | Validation | P-value |
|---|---|---|---|
| (n = 29) | (n = 79) | ||
| Age median in years (min-max) ¥ | 49.9 (39.7–55.2) | 55.3 (48.9–61.5) | 0.07 |
| Follow up median in years (min-max)¥ | 9.2 (7.7–10.1) | 11.0 (7.4–11.8) | 0.043 |
| Classification all samples^ | 0.37 | ||
| Benign | 10 (34%) | 30 (38%) | |
| Non-metastatic BC | 13 (45%) | 41 (52%) | |
| Metastatic BC | 6 (21%) | 8 (10%) | |
| Classification BRCA1-mutation carriers | (n = 5) | (n = 3) | |
| Benign | 3 | 1 | |
| Non-metastatic BC | 1 | 2 | |
| Metastatic BC | 1 | 0 | |
| Classification familial breast cancer^^ | (n = 6) | (n = 20) | |
| Benign | 0 | 8 (40%) | |
| Non-metastatic BC | 4 (67%) | 10 (50%) | |
| Metastatic BC | 2 (33%) | 2 (10%) | |
| Breast cancer patients | (n = 19) | (n = 49) | |
| Tumour stage^^ | 0.26 | ||
| T1 | 9 (47%) | 28 (57%) | |
| T2 | 7 (37%) | 19 (39%) | |
| T3 | 3 (16%) | 2 (4%) | |
| Nodal stage^^ | 0.12 | ||
| N0 | 5 (26%) | 25 (51%) | |
| N1 | 10 (53%) | 16 (33%) | |
| N2 | 3 (16%) | 4 (8%) | |
| N3 | 0 | 4 (8%) | |
| Unknown | 1 (5%) | 0 | |
| Oestrogen receptor status^ | 0.51 | ||
| Negative | 5 (26%) | 9 (18%) | |
| Positive | 14 (74%) | 40 (82%) | |
| Her2Neu receptor status^^ | 0.73 | ||
| Negative | 17 (89%) | 33 (67%) | |
| Positive | 2 (11%) | 9 (18%) | |
| Unknown | 0 | 7 (14%) | |
| Triple negative breast cancer* ^^ | 0.22 | ||
| No | 14 (74%) | 43 (88%) | |
| Yes | 5 (26%) | 5 (10%) | |
| Unknown | 0 | 1 (2%) |
BC - Breast Cancer. ¥ Mann–Whitney U test ^Fishers exact test with a Freeman-Halton extension when appropriate (2-tailed P-value). ^^Kruskall Wallis test. *ER-receptor, PR-receptor and Her2Neu receptor negative breast cancer.